To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Quartet's approach is somewhat analogous to so-called ...
An early-stage biotech formed two years ago at Atlas Venture has brought in another $6 million in funding and named two new board members as it works to develop new kinds of treatments for pain and ...